Compared to the evaluation of new pharmaceutical drugs, the assessments of the design and results of clinical trials for medical devices are not well established. For medical devices, the definition of the benefit-risk balance assessed during approval by regulatory agencies is not clear, which may result in subjectivity of the decision-making process. It is possible to hypothesize that the newly approved medical device should be superior in both risk and efficacy to the already existing device, which is used as control. To test this hypothesis, we performed an independent analysis of the premarket approvals (PMA) of therapeutic medical devices based on assessment review of reports of a regulatory agency, the Food and Drug Administration (FDA). A total of 74 studies that tested various medical devices for PMA were selected. For each clinical trial, the study design was evaluated with particular emphasis on its nature (retrospective or prospective). presence of a control arm, randomization, and masking. We performed an objective analysis of the benefit-risk balance between effectiveness and safety in the test arm compared to that in the control arm, using an original method for data evaluation. Of the 74 studies, 56 (76％) were prospective, 1 was purely retrospective (1％). 15 were mixed (20％), and 2 (3％) did not specify the nature of study. Only 46 studies (62％) included a comparative control group, 26 of which (57％) demonstrated "equivalence" but not "superiority" of the primary effectiveness measure. Depending on the evaluation criteria (mortality, complications, adverse effects, others) the results of safety assessment revealed advantage of the test arm in only 16-38％ of comparative studies. The designs of the protocols for testing therapeutic medical devices and the criteria of objective evaluation during approval for broad clinical practice are not standardized. For PMA approval, FDA does not ultimately require better effectiveness and/or safety of the new device compared to the existing control device.
Introduction
In recent years, dedicated multifaceted industrygovernment-academia research groups were established in Japan for the development of issues related to the socalled "regulatory science" . This term was originally related to the requirement of scientific approach in the development of new medications, upon which regulatory agencies operate, but its current use is wider and extends not only to issues related to medical pharmacology, but also to the approval of novel diagnostic and therapeutic equipment.
In the USA, premarket approval (PMA) is the most difficult and most expensive stage of the development process of medical devices, but this process is still not fully optimized or standardized. Compared to evaluation of new pharmaceutical drugs, assessments of the design and results of clinical trials for medical devices seem not well established z1, 2|. While it is generally considered that benefit-risk balance is the most important evaluating factor during approval of the tested medical devices by regulatory agencies, its strict definition is not clear and methods of its assessment during decision making appears somewhat subjective. At present, different groups of researchers in Japan are trying to define their own strategies to bring new medical equipment into clinical use as fast as possible. Under such conditions, the Japanese regulatory agency attempts to make the approval process transparent and promotes open discussions between representatives of industries, governmental bodies, and academic institutions. Since the decisionmaking process during development of new medical devices constitutes a very important aspect of the regulatory sciencez3|, our group decided to perform an analysis of approval criteria for new medical equipment used by the regulatory agency, using open access information available through the internet. Initially we planned to use the Japanese database, but it contains too limited number of approved domestic devices, which do not permit reliable evaluation of decision-making during the approval process. In order to overcome this problem, we decided to investigate a wide range of different devices as well as similar equipment produced by different manufactures. Therefore, we performed an independent analysis of the approval of therapeutic medical devices based on a review of the reports of a regulatory agency, the Food and Drug Administration (FDA).
We hypothesized that the newly approved medical device should be superior in both risk and efficacy to the already existing device used as control. Special emphasis was put on the design of the clinical trials. Herein, we report the final results of our investigationz4|.
Methods
For the purpose of the present study, a retrospective search of FDA database available on the internet (http:// www.accessdata.fda.gov/scripts/cdrh/cfdocs/cftopic/ mda/) was done. This site provides all essential information of recently approved devices under "CDRH Consumer Information."
Data selection
Between 2000 and 2008, 549 medical devices received PMA by FDA. However, 295 of them either overlapped (similarly named in different categories) or were designed specifically for diagnostic purposes. Of the remaining 259 devices, 180 had similar mechanisms of action within the same medical field and were therefore excluded. After excluding the above-mentioned 475 PMA reports of medical devices, 74 representative reports were selected for the present analysis ( Fig. 1) . However, 28 of the 74 reports did not note the use of a comparative control group.
Analysis
In the 74 selected reports on PMA of medical devices, the information on animal studies during preclinical testing was initially checked. For clinical trials of each medical device, the study design was evaluated with particular emphasis on its nature (retrospective or prospective), presence of control arm, randomization, and masking.
Detailed analysis was conducted on 46 devices that had undergone controlled clinical trials before PMA. In this group, we conducted an objective analysis of the benefit-risk balance between effectiveness and safety in the test arm compared to that in the control arm. For this purpose, effectiveness was estimated by primary or secondary endpoint, and safety by the presence of adverse events and/or side effects. An original method of evaluation was used. An effectiveness score of "+1" was assigned if the endpoint of the test arm was significantly better than that of the control arm, a score of "0" if no difference was found, and a score of "−1" if the endpoint was worse in the test arm. Correspondingly, if a trial had several endpoints, the scores were summed (for two endpoints both of which demonstrated advantages in the test arm, the score was : z+1| + z+1| =2). Safety was assessed in the same manner. A safety score of "+1" was assigned if the adverse events and/or side effects were significantly less prominent in the test arm compared to control arm. All devices were classified by the effectiveness and safety scores. Additionally, a "regulatory science score" (RS score) was defined as the sum of effectiveness score and safety score.
Statistics
Chi-square test was used for statistical comparison of effectiveness, safety, and RS scores. The level of significance was determined for two-tailed P-values less than 0.05.
Results
Among 74 reports on PMA of medical devices, information on preclinical animal studies was available in 46 (62％). Overall, 56 studies (76％) were prospective, 1 was purely retrospective (1％), 15 were mixed (20％), and 2 (3％) did not specify the nature of study. There were 29 randomized and 16 masked studies. Eleven of 16 masked studies were double-blind, 4 were single-blind, and 1 was mixed. Overall, 62 studies (84％) were multicenter, 4 were single center (5％), 5 were mixed (7％), and 3 (4％) did not specify. The number of participating centers was provided in 64 reports ; the mean number of centers was 20, and the mean number of enrolled patients was 317.
Studies without a control arm
As mentioned above, only 46 reports (62％) contained a comparative control group. Among 28 reports without comparative control, 13 did not use control group at all, 12 used either historical control or a combination of historical and prospectively designed control groups, whereas 3 studies did not provide any reliable information on this issue. Studies without a control arm were related to testing of a heart valve, cardiac defibrillators, aortic and mitral prostheses, a replaceable heart, a cardiac pacemaker, a ventricular assist device for children (with a clearly defined exemption from the usual study standards), a renal stent, a control system for Parkinson disease, a cardiac ablation device, breast implants, a urinary prosthesis to control incontinence, a spinal cord stimulation system, and a prosthesis for jaw surgery. More than half of all studies without control tested potentially lifesaving devices related to cardiac problems.
In studies without a control arm, effectiveness was usually assessed relative to the baseline levels of pretreatment parameters, whereas success was defined as a predetermined level of improvement of these parameters. In some cases, this level was determined from the published data in the literature and case studies. To facilitate the evaluation process, FDA applied Bayesian statistics to provide prospective attainment of the targeted parameters of interest. However, in many occasions, it was not possible to clarify how the required improvement relative to baseline was determined. In such cases, it was often stated that safety was "satisfactory" in terms of complications.
Studies with a control arm
Statistical analysis was used to compare primary endpoints in 39 of 46 studies with a control arm (85％). Secondary endpoints were evaluated in 31 studies, 25 of which applied statistical analysis to compare their data. Regarding the criterion for primary effectiveness, 26 of 46 (57％) studies with a control arm demonstrated"equivalence", but not "superiority" ( Table 1) . Among studies that compared secondary endpoint with a control, 8 devices were approved after demonstration of "equivalence" only (demonstration of "superiority" was not always required by study design).
Results of safety assessment in the 46 studies with a control arm are presented in Table 2 . Overall, depending on the evaluation criteria, the test arm demonstrated advantages in 16-38％ of studies only.
Evaluation of benefit-risk balance
Overall results of the evaluation of benefit-risk balance are shown in Fig. 2 as a two-dimensional map.
Using our original method to evaluate 46 studies with a control arm as described above, 8 devices (17％) demonstrated superior scores for both effectiveness and safety, 10 (22％) had superior effectiveness score and equivalent safety score, 9 (20％) showed superior effectiveness score but inferior safety score, and 14(30％) had equivalent scores for both effectiveness and safety. The 14 devices with equivalent effectiveness and safety scores Yoshihiro MURAGAKI, et al : Decisions on Premarket Approval of Medical Devices (103) Table 1   Table 2 showed smaller RS score compared to the other 32 devices (P=0.035). In contrast, the group of devices with superior effectiveness score (27 of 46 cases ; 59％) had greater RS score compared to the other 19 devices (P=0.013).
Discussion
Protocols for testing novel medical devices cannot simply copy the equivalent protocols for the evaluation of new pharmaceutical drugs, which nearly always include a control group and use randomization. Our analysis of PMA of therapeutic medical devices granted by FDA between 2000 and 2008 demonstrated that 20％ of the studies had only single arm, whereas the majority were not blinded or randomized. Such findings are consistent with the previous reports focusing exclusively on cardiovascular toolsz1, 2|. The studies without controls involved devices for a variety of health conditions, while more than a half of the studies tested potentially lifesaving devices related to cardiac problems. Therefore, it is possible to suspect that in such cases the testing requirements were simplified in order to allow quick approval of the devices with high life-saving potential for patients with heart diseases. In fact, an official statement of such policy was issued for trials of ventricular assist device for children. Nevertheless, testing of some other devices such as breast implants also did not include a control group for no obvious reason, since these devices cannot be considered to save life or maintain health.
Only 16 of the 74 studies analyzed were described as masked or partially masked (double-or single-blinded), while it is possible that such description was missed or omitted in some reports. This aspect is also different from the testing of pharmaceutical drugs for FDA approval, which must be double-blinded as a rule. Blind testing of many devices is evidently not possible. For example, if a placebo (sham) device is used in a trial, it cannot be masked easily. Nevertheless, since the patient is aware of the type of procedure performed in an unmasked fashion, when the patientʼs subjective scoring (such as quality of life and pain level) is included in evaluation of the device, the possible source of error should be taken into consideration. Moreover in many cases, use of the novel device requires special skills, and the learning curve may have potential influence on the results of the clinical trial, particularly in the surgical field.
For FDA approval, testing of pharmaceutical drugs requires unequivocal demonstration of superiority in terms of efficacy and/or safety compared to the control group. Meanwhile, our analysis of benefit-risk balance revealed that 30％ of the devices approved by FDA had equivalent scores for both effectiveness and safety compared to control group. While no approved therapeutic device showed inferior effectiveness compared to control, many of the approved devices did not demonstrate "superiority". In fact, regarding the primary endpoint, 57％ of studies with a control arm demonstrated only "equivalence" compared to the control group. These devices were frequently associated with equal or even inferior safety compared to control, which strongly suggests that FDA mainly regards effectiveness, or even Advanced Biomedical Engineering. Vol. 2, 2013. (104) Fig. 2 Benefit-risk map demonstrating effectiveness and safety scores of the tested devices in studies with a control arm (n=46).
potential effectiveness, of the device as the primary criterion for approval, and generally considers effectiveness as being more important than safety in terms of complications, adverse events, or other evaluation criteria (certainly, beside mortality). Therefore, a proof of "equivalence" for the safety parameters in the test group compared to control was usually sufficient for approval, and "superiority" was required in a few cases only. Ideally, as it was stated in the primary hypothesis of our study, the novel therapeutic device should be superior in both risk and efficacy to the already existing device used as control (Fig. 3) . However, the evaluation process of clinical trials may be rather complicated. Primary end points as well as the optimal number for such testing are not well established. To obtain objective evaluation of the benefit-risk balance, we presented an original method of data evaluation in the present study. Our method takes into consideration both comparative effectiveness and safety, and bases on calculation of the composite RS score.
A limitation of the present study is that only FDAapproved therapeutic devices were assessed. The inability to analyze cases in which PMA was declined does not permit examination of all details of the decision-making process. Moreover, the primary and secondary end points were not separated during objective analysis of the available data. Finally, it should be emphasized that it is difficult to determine precisely the effectiveness and safety of new devices and their influence on the national health system based on the PMA trials only. Recently FDA initiated postmarket surveillance of approved devices, but this aspect was not addressed in the present study. Further investigations should take these concerns into consideration.
Conclusion
The designs of protocols for testing therapeutic medical devices and the criteria of objective evaluation during approval for broad clinical practice are not standardized. According to the results of our investigation, FDA does not ultimately require superiority in effectiveness and/or safety of new devices compared to existing controls for PMA approval. (106)
